People suffering from psoriasis reported quick and extensive improvement of the psoriasis skin condition with new drug. The study published in The Lancet journal. 40% of people reported a complete clearance of psoriatic plaques after 12 weeks of treatment with the new drug and over 90% showed improvement.
The US Food and Drug Administration (FDA) has accepted for review Teva Pharmaceutical's Biologics License Application (BLA) for reslizumab for the treatment of inadequately controlled asthma in adult and adolescent patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen.

